IMBdx아이엠비디엑스
461030 · KOSDAQ · ₩461030 · 아이엠비디엑스
- Market cap
- ₩35B
- Enterprise value
- ₩19B
- P/E
- —
- P/B
- 1.5×
- Dividend yield
- 0.0%
- ROE
- −32.6%
- Net margin
- −135.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−80.9% from the high
₩1,910Today: ₩2,400 – ₩2,530₩12,950
Returns
- 1W−2.9%
- 1M−13.0%
- 3M−4.6%
- 6M−65.4%
- YTD−75.0%
- 1Y−77.9%
- Volume today
- 14,271
- 0.8× the 20-day average
- Traded today
- ₩35M
- Listed shares
- 14,334,517
- EPS (12 months)
- −₩529
- Earnings yield −21.4%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumWeak-9.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
IMBdx stock overview
IMBdx (아이엠비디엑스, KRX: 461030) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean healthcare firm built on liquid biopsy technology, which analyzes DNA fragments circulating in blood and other body fluids to support cancer care across its life cycle. Its shares closed at ₩2,475 on Oct 28, 2026, down 1.39% on the day, giving it a market value of ₩35B.
Key facts
- Market cap
- ₩35B
- Sector
- Biotech & Pharma
- Latest price change
- −1.39%
- As of
- Oct 28, 2026
- Main business
- The company is a Korean healthcare firm built on liquid biopsy technology, which analyzes DNA fragments circulating in blood and other body fluids to support cancer care across its life cycle.
Quick answers about IMBdx
- What does IMBdx do?
- The company is a Korean healthcare firm built on liquid biopsy technology, which analyzes DNA fragments circulating in blood and other body fluids to support cancer care across its life cycle. Its three main business areas are precision diagnosis and treatment of advanced cancer through profiling products such as AlphaLiquid100 and AlphaLiquid HRR, early detection of recurrence after surgery through its CancerDetect product, and multi-cancer early screening through its CancerFind product. The business operates globally, with products for patients and healthcare providers, and relies on purchased reagents, probes and sequencing flowcells, largely from foreign suppliers.
- What is the market cap of IMBdx?
- The market capitalisation of IMBdx was ₩35B at the close on Oct 28, 2026.
- Who are the largest shareholders of IMBdx?
- According to the latest official filings, the largest reported holders are Kim Tae-yoo (13.25%, as of Jun 30, 2026); National Pension Service (0.31%, as of Dec 31, 2024); Kim Hwang-pil (0.23%, as of Jul 9, 2026).
- When is the next earnings report from IMBdx?
- Korean companies rarely announce results dates in advance. Based on when IMBdx filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own IMBdx?
- Yes. The National Pension Service held 0.31% of IMBdx shares as of Dec 31, 2024.
Company profile
The company is a Korean healthcare firm built on liquid biopsy technology, which analyzes DNA fragments circulating in blood and other body fluids to support cancer care across its life cycle. Its three main business areas are precision diagnosis and treatment of advanced cancer through profiling products such as AlphaLiquid100 and AlphaLiquid HRR, early detection of recurrence after surgery through its CancerDetect product, and multi-cancer early screening through its CancerFind product. The business operates globally, with products for patients and healthcare providers, and relies on purchased reagents, probes and sequencing flowcells, largely from foreign suppliers.
Written by AI from the company's latest annual report.
- Korean name
- 아이엠비디엑스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김태유
- Founded
- Jul 2018
- Listed
- Apr 2024
- Listed shares
- 14,334,517
- Fiscal year ends
- Month 12
- Website
- www.imbdx.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJul 9, 2026
- Insider shareholding reportJul 7, 2026
- Insider shareholding reportJun 30, 2026
- Insider shareholding reportJun 30, 2026
Titles in Korean until English translations are added.
Also known as: IMBdx / 아이엠비디엑스 / 461030 / KRX:461030
Source: KRX statistical information